Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study–Rationale and design of the PACMAN-AMI trial-Reference-Cited by-同舟云学术

Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study–Rationale and design of the PACMAN-AMI trial

Published:2021-08 Issue: Volume:238 Page:33-44
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Zanchin Christian^ORCID,Koskinas Konstantinos C.,Ueki Yasushi,Losdat Sylvain,Häner Jonas D.,Bär Sarah,Otsuka Tatsuhiko,Inderkum Andrea,Jensen Maria Radu Juul,Lonborg Jacob,Fahrni Gregor,Ondracek Anna S.,Daemen Joost,van Geuns Robert-Jan,Iglesias Juan F.,Matter Christian M.,Spirk David,Juni Peter,Mach Francois,Heg Dik,Engstrom Thomas,Lang Irene,Windecker Stephan,Räber Lorenz

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials;Baigent;The Lancet,2010

2. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: A meta-analysis of randomized trials;Koskinas;Eur Heart J,2018

3. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

4. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines;Koskinas;Eur J Prev Cardiol,2021

5. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;New Engl J Med,2017

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction;JAMA Cardiology;2024-09-02

2. Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis;BMC Cardiovascular Disorders;2024-07-30

3. Safety and efficacy of PCSK9 inhibitor (evolocumab) in patients with non-ST segment elevation acute coronary syndrome and non-culprit artery critical lesions: a randomised controlled trial protocol (SPECIAL study);BMJ Open;2024-07

4. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy;Atherosclerosis;2024-05

5. Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome;Innovative Medicine of Kuban;2024-04-29